Affinage

Showing TJP2ZO-2 is a alias.

TJP2

Tight junction protein 2 · UniProt Q9UDY2

Length
1190 aa
Mass
134.0 kDa
Annotated
2026-06-10
95 papers in source corpus 43 papers cited in narrative 43 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 9/9 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TJP2 (ZO-2) is a MAGUK-family scaffold protein that organizes epithelial tight junctions and couples them to transcriptional and cytoskeletal control of cell growth (PMID:8132716, PMID:16923393). As a tight junction-associated peripheral membrane protein bearing three PDZ domains, an SH3 domain, and a guanylate kinase-like domain, it directly binds claudins via PDZ1, ZO-1, occludin, and F-actin, physically linking transmembrane junction components to the cortical actin cytoskeleton (PMID:8824195, PMID:10601346, PMID:10575001). ZO-1 and ZO-2 independently determine where claudins polymerize into tight junction strands, and cells lacking both fail to form tight junctions altogether; either protein alone restores strand assembly (PMID:16923393), and ZO-2 loss impairs both gate and fence functions and delays junctional protein recruitment (PMID:17374535). ZO-2 is essential in development, as its knockout causes peri-implantation embryonic lethality from gastrulation arrest (PMID:18172007). Beyond the junction, ZO-2 undergoes regulated nuclear-cytoplasmic shuttling governed by amino-terminal NLS sequences, multiple leptomycin B-sensitive nuclear export signals, SUMOylation at K730, K48-polyubiquitination at K759/K992, and 14-3-3 binding, which together tune its abundance and localization (PMID:15194440, PMID:16920099, PMID:27604867, PMID:36291162, PMID:31318316). In the nucleus it represses transcription, down-regulating AP-1 target genes and repressing cyclin D1 by recruiting c-Myc and HDAC1 to an E-box, thereby restraining proliferation (PMID:14720506, PMID:17881732). ZO-2 acts as a Hippo-pathway scaffold, binding LATS1 through its SH3 domain and YAP through its PDZ domains to promote LATS1-mediated phosphorylation and cytoplasmic retention of YAP, enforcing contact inhibition of proliferation; its loss drives nuclear YAP/TEAD activity, PTEN suppression, Akt/mTOR signaling and cellular hypertrophy (PMID:27009203, PMID:34689705, PMID:39462647, PMID:34010016). ZO-2 also localizes to centrioles and spindle poles, where it supports mitotic spindle microtubule stability and primary cilium formation (PMID:40728639). In humans, protein-truncating TJP2 mutations cause failure of tight-junction localization and progressive cholestatic liver disease, recapitulated by liver-specific deletion in mice that mislocalizes bile transporters and disrupts canalicular architecture (PMID:24614073, PMID:33465371).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 1994 High

    Established TJP2/ZO-2 as a distinct tight junction-associated MAGUK protein, answering whether it was a bona fide junctional component separate from ZO-1.

    Evidence Co-immunoprecipitation with ZO-1 from MDCK cells and immunolocalization across epithelial tissues

    PMID:8132716

    Open questions at the time
    • Direct binding partners at the junction not yet mapped to specific domains
    • Functional role beyond ZO-1 association unknown
  2. 1996 Medium

    Defined the modular domain architecture (three PDZ, SH3, GK domains) and divergent C-terminus, framing how ZO-2 might engage distinct ligands from ZO-1.

    Evidence Full-length cDNA sequencing and comparative sequence analysis

    PMID:8824195

    Open questions at the time
    • Functional assignment of individual domains not tested
    • Significance of the alternatively spliced region unresolved
  3. 1999 High

    Resolved how ZO-2 bridges transmembrane junction proteins to the cytoskeleton, identifying claudin (PDZ1), ZO-1, occludin, F-actin, and cingulin as direct partners.

    Evidence In vitro binding with recombinant PDZ domains, actin cosedimentation, co-immunoprecipitation in MDCK and epithelial lysates

    PMID:10575001 PMID:10601346 PMID:10613913

    Open questions at the time
    • Stoichiometry and dynamics of the claudin/ZO complex in living strands not defined
    • Whether ZO-2 actin binding is regulated unaddressed
  4. 2000 High

    Extended the cytoskeletal linkage by mapping a 4.1R/spectrin connection through a defined ZO-2 segment, reinforcing a tight-junction-to-actin scaffold.

    Evidence Yeast two-hybrid, in vitro binding, co-immunoprecipitation, immunocolocalization in MDCK cells

    PMID:10874042

    Open questions at the time
    • Functional consequence of disrupting the 4.1R/ZO-2 link not tested
    • Tissue-specificity of the interaction unknown
  5. 2002 Medium

    Revealed a non-junctional nuclear pool of ZO-2 that shuttles in a density- and export-dependent manner and binds nuclear partners, opening a transcriptional role.

    Evidence Confluence-dependent immunofluorescence, leptomycin B sensitivity, yeast two-hybrid and co-IP with SAF-B

    PMID:11855865 PMID:12403786

    Open questions at the time
    • Transcriptional output of nuclear ZO-2 not yet demonstrated
    • Import/export signals not yet mapped
  6. 2004 Medium

    Defined ZO-2 as a transcriptional repressor and mapped its NLS/NES shuttling determinants, linking junctional localization to gene control of AP-1 targets.

    Evidence Pull-down, EMSA, co-IP with Jun/Fos/C-EBP, reporter assays, nuclear fractionation and NLS/NES mutant analysis

    PMID:14720506 PMID:15194440

    Open questions at the time
    • Direct DNA binding excluded but full repressor complex undefined
    • Physiological triggers of nuclear entry incomplete
  7. 2006 High

    Demonstrated that ZO-1 and ZO-2 are independently sufficient to drive claudin polymerization and tight-junction strand formation, establishing a core organizational function.

    Evidence ZO-1 KO/ZO-2 knockdown cells with domain-mapped rescue, immunofluorescence, TER measurement

    PMID:16920099 PMID:16923393

    Open questions at the time
    • Mechanism by which scaffolds template claudin polymerization not structurally defined
    • Relative in vivo contributions of ZO-1 vs ZO-2 unresolved
  8. 2007 High

    Showed ZO-2 controls both gate and fence functions and the kinetics of junctional protein assembly, and represses cyclin D1 to restrain proliferation, linking junction integrity to growth control.

    Evidence siRNA knockdown with TER/dextran flux/calcium switch assays; reporter, EMSA, ChIP and co-IP for cyclin D1 repression via c-Myc/HDAC1

    PMID:17374535 PMID:17881732

    Open questions at the time
    • How junctional vs nuclear pools coordinate growth signaling not dissected
    • HDAC1 recruitment mechanism partial
  9. 2008 High

    Established the in vivo essentiality of ZO-2 (embryonic lethality) and its role in adherens junction maturation via RhoA-dependent myosin-2 integration.

    Evidence ZO-2 and ZO-3 knockout mice with histology/permeability assays; ZO-1/ZO-2 double-depletion with FRET Rho activation and rescue

    PMID:18172007 PMID:18596233 PMID:18817772

    Open questions at the time
    • Molecular basis of gastrulation arrest unresolved
    • Link between Rho regulation and junction defect mechanistically incomplete
  10. 2010 Medium

    Connected ZO-2 to YAP, showing PDZ1-dependent complex formation that modulates YAP nuclear localization and function, foreshadowing a Hippo-pathway role.

    Evidence Co-IP, colocalization, PDZ-deletion mutants, nuclear localization and apoptosis assays

    PMID:20868367

    Open questions at the time
    • Context-dependence of pro- vs anti-growth YAP outcomes unclear
    • Upstream Hippo kinase link not yet established
  11. 2014 High

    Established TJP2 truncating mutations as a cause of human progressive cholestatic liver disease through failed junctional localization, defining a Mendelian disease link.

    Evidence Next-generation sequencing and patient liver biopsy immunohistochemistry/electron microscopy

    PMID:24614073

    Open questions at the time
    • Mechanism connecting junction disruption to bile transport not yet defined in vivo
    • Species difference vs embryonic-lethal mouse unexplained
  12. 2016 High

    Linked ZO-2 loss to cellular hypertrophy through dual cyclin D1 (G1) and YAP-PTEN-Akt/mTOR mechanisms, and mapped SUMOylation (K730) as a shuttling switch that also tunes GSK3-beta and beta-catenin signaling.

    Evidence siRNA knockdown with cell-cycle/protein-synthesis/signaling readouts and uninephrectomy rat model; Ubc9/SENP SUMOylation assays and K730R mutagenesis

    PMID:27009203 PMID:27604867

    Open questions at the time
    • Direct LATS link to YAP regulation not yet shown here
    • How SUMO and other PTMs are integrated in vivo unclear
  13. 2019 Medium

    Defined PTM- and 14-3-3-controlled regulation of ZO-2 stability and localization downstream of calcium/CaSR-PKC-WNK4 signaling, explaining how junction assembly is dynamically tuned.

    Evidence Co-IP, CaSR/PKC/WNK4 pharmacology, S261 and unique-region-2 mutagenesis, immunofluorescence

    PMID:31318316

    Open questions at the time
    • Physiological calcium contexts driving this in vivo not addressed
    • Interplay with SUMO/ubiquitin codes not integrated
  14. 2021 High

    Solidified ZO-2 as a Hippo scaffold and TEAD-localization regulator, and established cell-type-specific liver phenotypes including YAP/TAZ-dependent hepatocyte transdifferentiation.

    Evidence Co-IP with LATS1, PLA/pull-down for TEAD, nPKC pharmacology, conditional liver Tjp2 KO with cholic acid/DDC challenge and Yap/Taz genetic epistasis

    PMID:33465371 PMID:34010016 PMID:34689705 PMID:36151109

    Open questions at the time
    • Quantitative contribution of junctional vs nuclear ZO-2 to Hippo output unresolved
    • How transporter mislocalization arises mechanistically incomplete
  15. 2022 Medium

    Mapped K48-polyubiquitination acceptor sites (K759/K992) controlling ZO-2 half-life and showed PTM crosstalk with the K730 SUMO site, tying degradation control to tight-junction sealing.

    Evidence TUBE assay, ubiquitin co-IP, K730/K759/K992 mutagenesis, cycloheximide chase, TER measurement

    PMID:36291162

    Open questions at the time
    • E3 ligase responsible for ZO-2 ubiquitination not identified
    • In vivo relevance of half-life control untested
  16. 2023 Medium

    Extended ZO-2's growth-suppressive scaffolding into LATS-dependent contact inhibition and tumor suppression via p190A RhoGAP, and into ERK2 modulation downstream of ZNF582.

    Evidence Co-IP, siRNA knockdown, LATS kinase assays, in vivo tumorigenesis and proteomics/ccRCC models

    PMID:36966163 PMID:37995182

    Open questions at the time
    • Direct vs indirect nature of some interactions not fully resolved
    • Tissue-specificity of tumor-suppressive vs other roles unclear
  17. 2024 Medium

    Provided the domain-level mechanism by which ZO-2 scaffolds LATS1-YAP (SH3 binds LATS1, PDZ binds YAP) and stabilizes LATS1, and revealed ZO-2 control of junctional mechanics and tension.

    Evidence Co-IP with SH3/PDZ mutants, YAP phosphorylation and LATS1 stability assays; AFM and FRET tension probes with siRNA knockdown

    PMID:38473701 PMID:39462647

    Open questions at the time
    • Structural basis of the LATS1-ZO-2-YAP assembly not solved
    • How mechanical state feeds back to Hippo output incomplete
  18. 2025 Medium

    Uncovered non-junctional roles of ZO-2 at centrioles/spindle poles in microtubule stability and ciliogenesis, plus phosphoregulation by c-Abl/JAK1 and a requirement for NTCP surface display and HBV infection.

    Evidence Co-IP with ZO-2 segments, EB1 live imaging and spindle analysis; in vitro c-Abl kinase assay with RNAi rescue and traction force microscopy; LC-MS/MS, KD/KO and HBV infection assays

    PMID:40728639 PMID:41259016 PMID:41870046

    Open questions at the time
    • Mechanism coupling ZO-2 to spindle pole factors not structurally defined
    • Whether NTCP/HBV role generalizes beyond hepatocytes untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the integrated PTM code (SUMO/ubiquitin/phosphorylation/14-3-3) and the choice between junctional, nuclear, and centrosomal ZO-2 pools are coordinated in vivo to dictate barrier function versus growth control remains unresolved.
  • No structure of full-length ZO-2 in any scaffolding complex
  • E3 ligase and full PTM regulatory network unidentified
  • Causal link between junctional disruption and bile transporter mislocalization mechanistically incomplete

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 4 GO:0008092 cytoskeletal protein binding 2 GO:0098772 molecular function regulator activity 2 GO:0140110 transcription regulator activity 2
Localization
GO:0005634 nucleus 3 GO:0005886 plasma membrane 3 GO:0005654 nucleoplasm 2 GO:0005768 endosome 1 GO:0005815 microtubule organizing center 1 GO:0005929 cilium 1
Pathway
R-HSA-1500931 Cell-Cell communication 4 R-HSA-162582 Signal Transduction 4 R-HSA-1640170 Cell Cycle 3 R-HSA-1643685 Disease 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-1266738 Developmental Biology 2
Complex memberships
JAM-A/afadin/PDZ-GEF1/Rap2c moduleLATS1-ZO-2-YAP Hippo scaffoldtight junction

Evidence

Reading pass · 43 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1994 ZO-2 (TJP2) was found to coimmunoprecipitate with ZO-1 from MDCK cell extracts, identifying it as a tight junction-associated peripheral membrane protein that interacts with ZO-1. ZO-2 contains a region homologous to ZO-1 including guanylate kinase-like and PDZ domains (MAGUK family). ZO-2 localizes exclusively at cytoplasmic surfaces of tight junctions in epithelia (liver, intestine, kidney, testis, arterial endothelium) but is absent from the fascia adherens in cardiac myocytes, unlike ZO-1. Coimmunoprecipitation from MDCK cells, polyclonal antibody against unique ZO-2 region, immunohistochemistry of frozen tissue sections, double-label immunofluorescence The Journal of cell biology High 8132716
1996 ZO-2 contains three PDZ domains, an SH3 domain, and a guanylate kinase-like domain. An alternatively spliced 36-amino acid domain exists in the C-terminal proline-rich region. The PDZ and protein-binding domains are highly conserved relative to ZO-1, while the C-terminal regions are divergent (25% identity), suggesting distinct functions. Full-length cDNA sequencing and sequence analysis of multiple ZO-2 cDNAs The Journal of biological chemistry Medium 8824195
1999 ZO-2 binds directly to the COOH-terminal YV sequence of claudin-1 through -8 via its PDZ1 domain in vitro. In cells lacking ZO-1, ZO-2 is recruited to claudin-based networks through both PDZ2 (ZO-2)/PDZ2 (ZO-1) interactions and PDZ1 (ZO-2)/claudin-COOH interactions. In vitro binding assays with purified recombinant PDZ domains, transfection of claudins into L fibroblasts, immunofluorescence colocalization The Journal of cell biology High 10601346
1999 ZO-2 directly binds F-actin in vitro (cosedimentation assay) but does not act as an F-actin cross-linking protein and does not bind actin filament ends. ZO-2 also directly binds ZO-1 and occludin. Immunoprecipitation showed ZO-1 and ZO-2 exist primarily as independent ZO-1·ZO-2 complexes rather than a trimeric ZO-1·ZO-2·ZO-3 complex in situ. Actin cosedimentation assays with purified recombinant proteins, low-speed sedimentation analyses, immunoprecipitation, immunofluorescence colocalization in cytochalasin D-treated MDCK cells The Journal of biological chemistry High 10575001
1999 The NH2-terminal fragment of cingulin (residues 1-378) interacts in vitro with ZO-2 in pull-down assays from epithelial lysates. ZO-2 immunoprecipitates contain cingulin, confirming an in vivo interaction. Pull-down assays from epithelial and insect cell lysates, co-immunoprecipitation The Journal of cell biology Medium 10613913
2000 Protein 4.1R isoforms (135 and 150 kDa) specifically interact with ZO-2 via residues encoded by exons 19-21 of 4.1R and residues 1054-1118 of ZO-2, as determined by yeast two-hybrid, in vitro binding, and co-immunoprecipitation. 4.1R co-localizes with ZO-2 and occludin at MDCK tight junctions and co-precipitates with ZO-2, ZO-1, occludin, actin, and alpha-spectrin, suggesting 4.1R links the tight junction to the actin cytoskeleton through ZO-2. Yeast two-hybrid system, in vitro binding studies, immunocolocalization, immunoprecipitation, Western blot The Journal of biological chemistry High 10874042
2001 Adenovirus type 9 E4-ORF1 oncoprotein selectively targets ZO-2 (acting as a candidate tumor suppressor). Complex formation is mediated by the C-terminal PDZ-binding motif of Ad9 E4-ORF1 and the first PDZ domain of ZO-2. This interaction results in aberrant cytoplasmic sequestration of ZO-2. Overexpression of wild-type ZO-2 (but not mutant ZO-2 lacking PDZ2 and PDZ3) interfered with Ad9 E4-ORF1-induced focus formation. Co-immunoprecipitation, immunofluorescence colocalization, focus formation assay, ZO-2 overexpression/mutant rescue experiments The EMBO journal Medium 11598001
2002 ZO-2 localizes to the nucleus in sparse epithelial cultures, accumulating in clusters that partially colocalize with splicing factor SC35. Nuclear staining diminishes as cultures reach confluence. Nuclear-to-cytoplasm shuttling is sensitive to leptomycin B (nuclear export inhibitor) and is mediated by the actin cytoskeleton. ZO-2 shuttling to the nucleus uses a pre-existing pool, not newly synthesized protein. Immunofluorescence in MDCK cells at varying confluence, leptomycin B treatment, mechanical injury assay, cell-cell contact disruption, protein synthesis inhibition Experimental cell research Medium 11855865
2002 Nuclear ZO-2 directly interacts with the DNA-binding protein scaffold attachment factor-B (SAF-B) via its PDZ1 domain, as shown by yeast two-hybrid assays and in vivo co-immunoprecipitation. EGFP-ZO-2 and DsRed-SAF-B fusion proteins partially co-localize in nuclei of transfected epithelial cells. No association of SAF-B with ZO-1 was found. Yeast two-hybrid assay, co-immunoprecipitation from epithelial cells, confocal microscopy of fluorescently-tagged fusion proteins The Journal of biological chemistry Medium 12403786
2003 A mutation in the first PDZ domain of TJP2/ZO-2 (associated with familial hypercholanemia in Amish individuals) reduces PDZ1 domain stability and ligand binding in vitro. Hepatic tight junctions show a morphological change in individuals with this mutation. In vitro domain stability and ligand binding assays with recombinant PDZ1 domain mutant, electron microscopy of liver biopsies Nature genetics Medium 12704386
2003 Tyrosine phosphorylation of the C-terminal tail of occludin (by c-Src in vitro) markedly reduces its binding to ZO-2 (as well as ZO-1 and ZO-3), but does not affect occludin binding to F-actin. In vitro phosphorylation of GST-fused C-occludin by c-Src, in vitro binding assays with ZO-2 Biochemical and biophysical research communications Medium 12604349
2004 ZO-2 associates with transcription factors Jun, Fos, and C/EBP both at the nucleus and at tight junction regions of epithelial cells. This association was confirmed by pull-down assays, gel shift analysis, and co-immunoprecipitation. ZO-2 down-regulates AP-1-controlled gene transcription in a dose-dependent manner; both the amino and carboxyl domains of ZO-2 are capable of inhibiting gene transcription. Pull-down assays with ZO-2 GST fusion proteins, gel shift (EMSA), co-immunoprecipitation, immunolocalization, CAT reporter gene assays Experimental cell research Medium 14720506
2004 ZO-2 is present in the nuclear matrix and co-immunoprecipitates with lamin B1 and actin from nuclei of sparse cultures. ZO-2 contains multiple nuclear localization signals (NLS) at its amino region; deletion of these NLS diminishes nuclear import and impairs the ability to regulate AP-1-controlled transcriptional activity. ZO-2 contains a functional nuclear export signal (NES2) at the GK region that is leptomycin B-sensitive. Nuclear fractionation, co-immunoprecipitation from nuclear fractions, NLS deletion mutants transfection, nuclear export assay with ovalbumin-conjugated NES peptides, leptomycin B sensitivity, reporter gene assay Experimental cell research Medium 15194440
2004 ARVCF interacts with ZO-2 via a C-terminal PDZ-binding motif on ARVCF and the PDZ domains of ZO-2. Nuclear localization of ARVCF is dependent on this PDZ-binding motif and can be mediated specifically by the PDZ domains of ZO-2 (but not equivalently by ZO-1). Disruption of cell-cell adhesion releases ARVCF from the plasma membrane, with an increased fraction localizing to the nucleus. Co-immunoprecipitation, yeast two-hybrid, fluorescence microscopy, domain-mapping using PDZ-binding motif mutants, calcium-switch assay Molecular biology of the cell Medium 15456900
2005 hScrib (mammalian Scribble homolog) directly interacts with ZO-2 via two PDZ domains of hScrib and the C-terminal PDZ-binding motif of ZO-2. Both proteins colocalize at cell-cell junctions. A point mutation in the LRR of hScrib delocalizes it from the plasma membrane and abrogates the interaction with ZO-2. GST pull-down, co-immunoprecipitation, immunofluorescence colocalization, LRR point-mutant analysis FEBS letters Medium 15975580
2006 ZO-1 and ZO-2 independently determine where claudins are polymerized during tight junction strand formation. In cells lacking both ZO-1 and ZO-2 (ZO-1 knockout/ZO-2 knockdown), tight junctions are completely absent despite normal cell polarity. Re-expression of either ZO-1 or ZO-2 alone restores claudin polymerization and tight junction formation. A truncated ZO-1 containing only PDZ1-3 was insufficient; forced membrane recruitment and dimerization of this truncated form restored claudin polymerization. Homologous recombination, RNAi knockdown, exogenous rescue by transfection, immunofluorescence, transepithelial resistance measurement Cell High 16923393
2006 ZO-2 contains four nuclear export signals (NES-0, NES-1 in PDZ2; NES-2, NES-3 in GK region). NES-0 and NES-3 are functional and leptomycin B-sensitive. NES-1, previously thought non-functional, becomes active upon acquisition of negative charge at Ser369. Efficient nuclear exit of ZO-2 amino and middle segments requires paired NES; mutation of any single NES in full-length ZO-2 induces nuclear accumulation. Nuclear export assay using ovalbumin-conjugated NES peptides microinjected into nuclei of MDCK cells, leptomycin B sensitivity, transfection of full-length ZO-2 NES mutants Experimental cell research Medium 16920099
2007 ZO-2 silencing in MDCK cells increases paracellular permeability to dextran (gate function impairment), disrupts fence function (non-polarized E-cadherin distribution), decreases occludin and E-cadherin protein levels, delays arrival of ZO-1, occludin and E-cadherin to the plasma membrane during calcium switch, and produces atypical monolayer architecture with widened intercellular spaces, multistratification, and altered actin patterns. siRNA knockdown in MDCK cells, transepithelial electrical resistance measurement, dextran flux assay, calcium switch assay, immunofluorescence, Western blot Experimental cell research Medium 17374535
2007 ZO-2 down-regulates cyclin D1 transcription in a dose-dependent manner via an E box in the cyclin D1 promoter, reducing cell proliferation. ZO-2 does not directly bind DNA but recruits c-Myc (confirmed by EMSA, ChIP, and co-immunoprecipitation) and HDAC1 to the E box. HDAC activity is required for ZO-2-mediated repression. CAT reporter gene assays with cyclin D1 promoter deletions, EMSA, chromatin immunoprecipitation (ChIP), co-immunoprecipitation, HDAC inhibitor treatment, wound-healing proliferation assay Molecular biology of the cell High 17881732
2008 ZO-2 knockout mice die shortly after implantation due to arrest in early gastrulation, demonstrating a non-redundant and critical role of ZO-2 in mammalian development. ZO-2−/− embryos show decreased proliferation at E6.5, increased apoptosis at E7.5, altered apical junctional complex architecture, and increased paracellular permeability. ZO-3 knockout mice have no obvious phenotype, indicating ZO-3 is dispensable. Gene targeting (ZO-2 and ZO-3 knockout mice), embryo histology and immunohistochemistry, paracellular tracer permeability assay, TUNEL/BrdU assays Molecular and cellular biology High 18172007
2008 ZO-1 and ZO-2 are both required for integration of myosin-2 into the epithelial zonula adherens (ZA). In ZO-1/ZO-2 double-depleted cells, a fragmented adherens junction (prezonula-AJ) positive for E-cadherin and actin but negative for myosin-2 forms. Re-expression of full-length ZO-1 or ZO-2 (or ZO-1 lacking PDZ1/2 but not PDZ1/2/3) restores myosin-2 integration. ZO-1/ZO-2 regulate RhoA-dependent spatiotemporal Rho activation for ZA establishment. Conditional ZO-1 KO/ZO-2 KD cell lines, rescue by transfection of truncation mutants, immunofluorescence, FRET analysis of Rho activation, dominant-active RhoA/ROCK transfection Molecular biology of the cell High 18596233
2008 In mouse preimplantation embryos, ZO-2 is expressed from both maternal and embryonic genomes; maternal ZO-2 protein associates with nuclei in zygotes and early cleavage stages. ZO-2 siRNA knockdown in zygotes delayed blastocoel cavity formation but did not block cell proliferation. ZO-2-deficient embryos compensatorily increased ZO-1 (but not occludin) assembly at tight junctions. siRNA microinjection into mouse zygotes/2-cell embryos, immunofluorescence, quantitative junctional analysis, blastocoel measurement Experimental cell research Medium 18817772
2010 ZO-2 uses its first PDZ domain to form a complex with YAP2. Endogenous ZO-2 and YAP2 co-localize in the nucleus. ZO-2 facilitates the nuclear localization and pro-apoptotic function of YAP2 in a PDZ-domain-dependent manner. Co-immunoprecipitation, co-localization by immunofluorescence, PDZ-domain deletion mutant analysis, nuclear localization and apoptosis assays The Biochemical journal Medium 20868367
2010 Genomic duplication of TJP2 in a family with progressive nonsyndromic hearing loss DFNA51 leads to overexpression of TJP2 transcript and protein. TJP2 overexpression in affected family members leads to decreased phosphorylation of GSK-3β and altered expression of apoptosis-regulating genes, suggesting a mechanism for progressive hair cell death. SNP array genomic analysis, RT-PCR, Western blot, immunohistochemistry of inner ear tissue, phospho-GSK-3β Western blot, expression profiling of apoptosis genes American journal of human genetics Medium 20602916
2013 JAM-A directly associates with ZO-2 (and indirectly with afadin), and this complex together with PDZ-GEF1 activates the small GTPase Rap2c. siRNA-mediated downregulation of JAM-A, ZO-2, afadin, or PDZ-GEF1 results in enhanced epithelial permeability, indicating ZO-2 is a functional component of the JAM-A/afadin/PDZ-GEF1/Rap2c signaling module that regulates barrier function. Co-immunoprecipitation, siRNA knockdown, transepithelial resistance and permeability assays, GTPase activity assays Molecular biology of the cell Medium 23885123
2013 SNX27 interacts with ZO-2 via the PDZ domain of SNX27 and the C-terminal PDZ-binding motif of ZO-2. Upon tight junction disruption by calcium chelation, ZO-2 transiently localizes to SNX27-positive early endosomes. SNX27 depletion decreases ZO-2 (but not ZO-1) mobility at cell-cell contacts (FRAP) and increases junctional permeability to large solutes. Proteomic interaction screen, co-immunoprecipitation, confocal immunofluorescence, FRAP, siRNA knockdown, permeability assays The Biochemical journal Medium 23826934
2014 Protein-truncating mutations in TJP2 cause failure of protein localization to tight junctions and disruption of tight-junction structure, resulting in severe progressive cholestatic liver disease. This contrasts with embryonic-lethal knockout in mice, highlighting species and organ-specific redundancy differences. Next-generation sequencing, immunohistochemistry and electron microscopy of liver biopsies, protein localization studies in patient tissue Nature genetics High 24614073
2016 ZO-2 silencing in MDCK renal epithelial cells induces cell hypertrophy via two mechanisms: (1) prolonging G1 phase due to elevated cyclin D1, and (2) augmenting protein synthesis via nuclear accumulation and increased transcriptional activity of YAP, which decreases PTEN expression, elevating PIP3 and activating Akt/mTOR/S6K1 signaling. In uninephrectomized rats, compensatory renal hypertrophy is accompanied by decreased ZO-2 and nuclear YAP expression. siRNA knockdown in MDCK cells, cell cycle analysis, protein synthesis measurement, YAP localization and activity assays, PTEN/Akt/mTOR/S6K1 Western blot, uninephrectomy rat model, immunofluorescence Molecular biology of the cell High 27009203
2016 ZO-2 is SUMOylated by the SUMO machinery; it associates with E2 SUMO-conjugating enzyme Ubc9 and SUMO-deconjugating proteases SENP1 and SENP3. SUMOylation site K730 in human ZO-2 (GuK domain) was identified; mutation K730R results in prolonged nuclear localization. A construct mimicking constitutive SUMOylation (SUMO1ΔGG-ZO-2) localizes preferentially to the cytoplasm. ZO-2 directly binds GSK3β, and cytosolic SUMO1ΔGG-ZO-2 modulates GSK3β kinase activity. ZO-2 also forms a complex with β-catenin, and wild-type ZO-2 inhibits β-catenin/TCF-4 transcriptional activity. Co-immunoprecipitation, Ubc9 fusion-directed SUMOylation, SENP1 inhibition assays, site-directed mutagenesis (K730R), nuclear recruitment assay, reporter gene assay, GSK3β kinase activity assay Cellular and molecular life sciences Medium 27604867
2018 The organophosphate pesticide methamidophos (MET) forms covalent bonds with ZO-2 at serine, tyrosine, and lysine residues. MET induces phosphorylation of ZO-2 and reduces the interaction between ZO-2 and occludin. MET targets ubiquitination sites on ZO-2 (including a lysine residue), and mutation of a MET-target lysine residue in ZO-2 interferes with TJ sealing in epithelial cells. Mass spectrometry (covalent modification identification), co-immunoprecipitation, Western blot (phosphorylation), transfection of ZO-2 mutants into epithelial cells, transepithelial resistance measurement Toxicology and applied pharmacology Medium 30291936
2019 CaSR activation by Gd3+ triggers ZO-2 concentration at tight junctions via PKC activation, which phosphorylates and activates WNK4, which in turn phosphorylates ZO-2, inducing its TJ localization. In low calcium, ZO-2 is protected from degradation by association with 14-3-3 proteins (ζ and σ). The ZO-2/14-3-3 complexes move to cell borders upon calcium restoration and then dissociate. The unique region 2 of ZO-2 and S261 (within an NLS) are critical for the interaction with 14-3-3 proteins and for efficient nuclear importation. Co-immunoprecipitation, pharmacological inhibition (CaSR agonist Gd3+, PKC/WNK4 inhibitors), site-directed mutagenesis (S261 and unique region 2 mutants), immunofluorescence, Western blot Molecular biology of the cell Medium 31318316
2021 ZO-2 tight junction protein modulates nuclear accumulation of TEAD transcription factor. ZO-2 knockdown reduces nuclear TEAD; ZO-2 lacking NLS does not facilitate TEAD nuclear entry. Inhibition of nPKCδ in parental cells triggers cytoplasmic ZO-2/TEAD interaction and facilitates ZO-2/TEAD complex nuclear importation. nPKCε activates a ZO-2 nuclear export signal to enhance TEAD nuclear exit. ZO-2/TEAD interaction was confirmed by proximity ligation, co-immunoprecipitation, and pull-down assays. Proximity ligation assay, co-immunoprecipitation, pull-down assay, nPKCδ/ε inhibitor treatment, ZO-2 NLS mutant transfection, immunofluorescence of TEAD localization Molecular biology of the cell Medium 34010016
2021 Liver-specific deletion of Tjp2 in mice results in lower claudin-1 protein levels, dilated canaliculi, lower microvilli density, aberrant radixin and BSEP (Abcb11) distribution, and mild progressive cholestasis with reduced Abcb11/Bsep and Cyp2b10 expression. Cholic acid diet causes severe cholestasis and liver necrosis in Tjp2-deficient mice. Combined hepatocyte and cholangiocyte deletion was necessary for severe CA-induced injury. Conditional liver-specific Cre-lox knockout (hepatocyte-specific and cholangiocyte-specific), electron microscopy, immunostaining, biochemical analysis, FITC-dextran permeability assay, cholic acid diet challenge Gastroenterology High 33465371
2021 ZO-2 associates with LATS1 (Hippo kinase), functioning as a scaffold for the Hippo pathway. ZO-2 silencing is accompanied by diminished LATS activity and nuclear concentration of YAP in renal epithelial cells, in uninephrectomized rat kidneys, and in liver steatosis in obese Zucker rats. Co-immunoprecipitation (ZO-2/LATS1), immunofluorescence of YAP localization, LATS kinase activity assay, siRNA knockdown, in vivo uninephrectomy rat model, obese Zucker rat model Tissue barriers Medium 34689705
2022 Liver-specific Tjp2 deletion in mice leads to DDC-diet-induced hepatocyte-to-cholangiocyte transdifferentiation, which is Yap/Wwtr1(Taz)-dependent and cell-autonomous to hepatocytes (not cholangiocytes). Tjp2 inactivation is sufficient to upregulate Yap and Taz protein expression in hepatocytes, but efficient transdifferentiation additionally requires the DDC-diet insult. Notch2 is not required. Conditional Tjp2 KO (hepatocyte-specific and cholangiocyte-specific), DDC diet challenge, Yap/Taz genetic inactivation experiments, immunostaining, lineage tracing NPJ Regenerative medicine Medium 36151109
2022 Residues K759 and K992 in human ZO-2 are acceptors for K48-linked polyubiquitination (targeting for proteasomal degradation); mutation to arginine increases ZO-2 half-life from ~20 to ~37 h. Residue K730 (the SUMOylation site) mutation increases ubiquitination and decreases ZO-2 half-life to ~6.7 h. Mutations at K759, K992, or K730 all decrease the TJ sealing peak (transepithelial resistance). Co-immunoprecipitation with ubiquitin antibodies, TUBE (tandem ubiquitin-binding entity) assay for K48-polyubiquitin, site-directed mutagenesis of K730, K759, K992, half-life measurement by cycloheximide chase, transepithelial resistance measurement Cells Medium 36291162
2023 ZNF582 binds to TJP2/ZO-2 protein and upregulates TJP2 protein expression. Increased TJP2 combines with ERK2 to promote ERK2 protein expression and suppresses phosphorylation of ERK2, thereby inhibiting ccRCC growth and metastasis. TMT quantitative proteomics, co-immunoprecipitation, Western blot, cell phenotype and orthotopic tumor experiments Cell death & disease Medium 36966163
2023 p190A RhoGAP interacts with ZO-2 in a manner dependent on RasGAP. Both RasGAP and ZO-2 are required for p190A to activate LATS kinases, elicit mesenchymal-to-epithelial transition, promote contact inhibition, suppress tumorigenesis, and transcriptionally modulate target genes. Low ARHGAP35 expression combined with high TJP2 expression predicts shorter survival. Co-immunoprecipitation, siRNA knockdown of ZO-2/RasGAP, LATS kinase activity assay, cell proliferation/contact inhibition assays, in vivo tumorigenesis models, reporter gene assay Cell reports Medium 37995182
2024 ZO-2 is required for contact-mediated inhibition of proliferation. ZO-2 acts as a scaffold that promotes LATS1-YAP interaction: ZO-2 binds LATS1 via its SH3 domain and YAP via its PDZ domains, thereby facilitating LATS1-mediated phosphorylation of YAP, leading to YAP cytoplasmic retention and inactivation. ZO-2 also promotes LATS1 stability. Co-immunoprecipitation with domain-specific ZO-2 mutants (SH3 and PDZ domain mutations), YAP phosphorylation assay, cell proliferation/contact inhibition assays, LATS1 stability measurement The FEBS journal Medium 39462647
2024 ZO-2 loss reduces apical membrane rigidity (measured by AFM), inhibits γ-actin and JAM-A recruitment to the cell border, and facilitates p114RhoGEF and afadin accumulation at junctions, leading to increased TJ mechanical tension (measured by FRET ZO-1 tension probe) and increased tricellular TJ tension. ZO-2 KD cells show impaired responses to substrate stiffness and topography, and increased nuclear YAP and Snail. Atomic force microscopy, FRET tension probes (ZO-1 and E-cadherin), immunofluorescence, siRNA knockdown, AFM membrane rigidity measurement, nanostructured substrate assays International journal of molecular sciences Medium 38473701
2025 ZO-2 colocalizes with CEP164 at the distal appendage of the mother centriole and is present at mitotic spindle poles, the basal body of primary cilia, and the tail of spermatozoa. ZO-2 depletion inhibits astral and mitotic spindle microtubule (EB1-expressing) development, reduces KIF14 and TPX2 at spindle poles, increases NuMA accumulation, and decreases p-Aurora levels, leading to reduced spindle length, microtubule instability, and abnormal chromosome congression. ZO-2 co-immunoprecipitates with KIF14, NuMA, and p-Aurora; NuMA and Aurora-A bind different segments of ZO-2. ZO-2 depletion also reduces primary cilium development and blocks Sonic Hedgehog signaling. Co-immunoprecipitation with ZO-2 segments, immunofluorescence colocalization, siRNA knockdown, spindle length and morphology analysis, EB1 live imaging, SHH reporter assay Cell and tissue research Medium 40728639
2025 c-Abl kinase directly binds to and phosphorylates the C-terminus of ZO-2, and also stimulates JAK1, which subsequently phosphorylates the N-terminus of ZO-2. c-Abl regulates cellular morphology and migration through ZO-2 phosphorylation (demonstrated by RNAi knockdown/rescue strategy). c-Abl activity is associated with decreased traction forces on the substrate. In vitro kinase assay (c-Abl phosphorylation of ZO-2 C-terminus), immunoprecipitation of c-Abl/ZO-2 complex, RNAi knockdown/rescue, traction force microscopy, cell migration assay FASEB journal Medium 41259016
2026 ZO-2 directly binds to NTCP (the HBV receptor sodium taurocholate cotransporting polypeptide), and this interaction is required for NTCP cell surface localization. ZO-2 knockdown or knockout decreases NTCP at the cell surface, reducing HBV attachment and infection. HBV surface protein preS1 binding causes dissociation of the NTCP/ZO-2 complex and formation of NTCP-preS1-actin complexes that internalize into cells. Actin polymerization is required for preS1 internalization and HBV infection (latrunculin A blocks this). ZO-1 and ZO-3 knockdown had no effect on HBV infection. Immunopurification/LC-MS/MS (interaction discovery), co-immunoprecipitation, ZO-2 KD/KO, NTCP cell surface flow cytometry, HBV infection assay, preS1 binding assay, latrunculin A treatment mBio Medium 41870046

Source papers

Stage 0 corpus · 95 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1999 Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. The Journal of cell biology 923 10601346
2006 ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 661 16923393
1994 Molecular characterization and tissue distribution of ZO-2, a tight junction protein homologous to ZO-1 and the Drosophila discs-large tumor suppressor protein. The Journal of cell biology 398 8132716
1999 Protein interactions at the tight junction. Actin has multiple binding partners, and ZO-1 forms independent complexes with ZO-2 and ZO-3. The Journal of biological chemistry 384 10575001
2006 Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cellular microbiology 312 17087734
1993 Monoclonal antibody 7H6 reacts with a novel tight junction-associated protein distinct from ZO-1, cingulin and ZO-2. The Journal of cell biology 230 8421059
1999 Cingulin contains globular and coiled-coil domains and interacts with ZO-1, ZO-2, ZO-3, and myosin. The Journal of cell biology 229 10613913
2003 Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nature genetics 213 12704386
2014 Mutations in TJP2 cause progressive cholestatic liver disease. Nature genetics 207 24614073
2010 Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. The Biochemical journal 173 20868367
2003 Tyrosine phosphorylation of occludin attenuates its interactions with ZO-1, ZO-2, and ZO-3. Biochemical and biophysical research communications 156 12604349
2008 Early embryonic lethality of mice lacking ZO-2, but Not ZO-3, reveals critical and nonredundant roles for individual zonula occludens proteins in mammalian development. Molecular and cellular biology 153 18172007
2002 Nuclear localization of the tight junction protein ZO-2 in epithelial cells. Experimental cell research 152 11855865
2004 The tight junction protein ZO-2 associates with Jun, Fos and C/EBP transcription factors in epithelial cells. Experimental cell research 134 14720506
2002 The tight junction protein ZO-2 localizes to the nucleus and interacts with the heterogeneous nuclear ribonucleoprotein scaffold attachment factor-B. The Journal of biological chemistry 131 12403786
2000 Characterization of the interaction between protein 4.1R and ZO-2. A possible link between the tight junction and the actin cytoskeleton. The Journal of biological chemistry 125 10874042
2000 Tight junction proteins ZO-1, ZO-2, and occludin along isolated renal tubules. Kidney international 112 10844608
2017 An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Scientific reports 107 28924228
1998 Subcellular distribution of tight junction-associated proteins (occludin, ZO-1, ZO-2) in rodent skin. The Journal of investigative dermatology 107 9620290
2013 JAM-A associates with ZO-2, afadin, and PDZ-GEF1 to activate Rap2c and regulate epithelial barrier function. Molecular biology of the cell 103 23885123
1996 The tight junction protein ZO-2 contains three PDZ (PSD-95/Discs-Large/ZO-1) domains and an alternatively spliced region. The Journal of biological chemistry 91 8824195
2009 Roles of ZO-1 and ZO-2 in establishment of the belt-like adherens and tight junctions with paracellular permselective barrier function. Annals of the New York Academy of Sciences 87 19538286
2010 Genomic duplication and overexpression of TJP2/ZO-2 leads to altered expression of apoptosis genes in progressive nonsyndromic hearing loss DFNA51. American journal of human genetics 83 20602916
2004 Association of ARVCF with zonula occludens (ZO)-1 and ZO-2: binding to PDZ-domain proteins and cell-cell adhesion regulate plasma membrane and nuclear localization of ARVCF. Molecular biology of the cell 81 15456900
2007 ZO-2 silencing in epithelial cells perturbs the gate and fence function of tight junctions and leads to an atypical monolayer architecture. Experimental cell research 79 17374535
2007 Cyclin D1 is transcriptionally down-regulated by ZO-2 via an E box and the transcription factor c-Myc. Molecular biology of the cell 79 17881732
2001 Link of the unique oncogenic properties of adenovirus type 9 E4-ORF1 to a select interaction with the candidate tumor suppressor protein ZO-2. The EMBO journal 76 11598001
2004 Characterization of the tight junction protein ZO-2 localized at the nucleus of epithelial cells. Experimental cell research 71 15194440
2009 Angiopoietin-1 reduces vascular endothelial growth factor-induced brain endothelial permeability via upregulation of ZO-2. International journal of molecular medicine 67 19148554
2006 Altered expression of ZO-1 and ZO-2 in Sertoli cells and loss of blood-testis barrier integrity in testicular carcinoma in situ. Neoplasia (New York, N.Y.) 66 17217619
2010 Assessments of tight junction proteins occludin, claudin 5 and scaffold proteins ZO1 and ZO2 in endothelial cells of the rat blood-brain barrier: cellular responses to neurotoxicants malathion and lead acetate. Neurotoxicology 63 20970449
2000 Organization and expression of the human zo-2 gene (tjp-2) in normal and neoplastic tissues. Biochimica et biophysica acta 63 11018256
2005 hScrib interacts with ZO-2 at the cell-cell junctions of epithelial cells. FEBS letters 62 15975580
2008 ZO-1- and ZO-2-dependent integration of myosin-2 to epithelial zonula adherens. Molecular biology of the cell 60 18596233
2015 Mutations in TJP2, encoding zona occludens 2, and liver disease. Tissue barriers 50 26451340
2008 Heterocellular interaction enhances recruitment of alpha and beta-catenins and ZO-2 into functional gap-junction complexes and induces gap junction-dependant differentiation of mammary epithelial cells. Experimental cell research 49 18775424
2017 Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing. Journal of gastroenterology 48 29238877
1999 Tight junction protein ZO-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma. International journal of cancer 48 10360833
2016 ZO-2 silencing induces renal hypertrophy through a cell cycle mechanism and the activation of YAP and the mTOR pathway. Molecular biology of the cell 47 27009203
2007 Identification, tissue distribution and developmental expression of tjp1/zo-1, tjp2/zo-2 and tjp3/zo-3 in the zebrafish, Danio rerio. Gene expression patterns : GEP 39 17632043
2008 Tight junction protein ZO-2 expression and relative function of ZO-1 and ZO-2 during mouse blastocyst formation. Experimental cell research 36 18817772
2006 The tight junction protein ZO-2 has several functional nuclear export signals. Experimental cell research 35 16920099
2021 Protective Functions of ZO-2/Tjp2 Expressed in Hepatocytes and Cholangiocytes Against Liver Injury and Cholestasis. Gastroenterology 31 33465371
2012 ZO-2, a tight junction scaffold protein involved in the regulation of cell proliferation and apoptosis. Annals of the New York Academy of Sciences 28 22671599
2014 ZO-1 and ZO-2 are required for extra-embryonic endoderm integrity, primitive ectoderm survival and normal cavitation in embryoid bodies derived from mouse embryonic stem cells. PloS one 26 24905925
2008 Bile duct ligation in the rat causes upregulation of ZO-2 and decreased colocalization of claudins with ZO-1 and occludin. Histochemistry and cell biology 26 18197414
2019 TJP2 hepatobiliary disorders: Novel variants and clinical diversity. Human mutation 25 31696999
2018 Effects of the differential expression of ZO-1 and ZO-2 on podocyte structure and function. Genes to cells : devoted to molecular & cellular mechanisms 24 29845705
2013 Sorting nexin 27 (SNX27) associates with zonula occludens-2 (ZO-2) and modulates the epithelial tight junction. The Biochemical journal 24 23826934
2018 The organophosphate pesticide methamidophos opens the blood-testis barrier and covalently binds to ZO-2 in mice. Toxicology and applied pharmacology 22 30291936
1999 zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells. International journal of cancer 22 10495427
2009 The tight junction protein ZO-2 blocks cell cycle progression and inhibits cyclin D1 expression. Annals of the New York Academy of Sciences 21 19538296
2015 Identification of Two Disease-causing Genes TJP2 and GJB2 in a Chinese Family with Unconditional Autosomal Dominant Nonsyndromic Hereditary Hearing Impairment. Chinese medical journal 20 26668150
2019 Novel compound heterozygote mutations of TJP2 in a Chinese child with progressive cholestatic liver disease. BMC medical genetics 19 30658709
2013 Papillomavirus E6 oncoprotein up-regulates occludin and ZO-2 expression in ovariectomized mice epidermis. Experimental cell research 19 23948304
2014 Different effects of ZO-1, ZO-2 and ZO-3 silencing on kidney collecting duct principal cell proliferation and adhesion. Cell cycle (Georgetown, Tex.) 18 25486565
2016 SUMOylation regulates the intracellular fate of ZO-2. Cellular and molecular life sciences : CMLS 17 27604867
2019 Activation of the Ca2+ sensing receptor and the PKC/WNK4 downstream signaling cascade induces incorporation of ZO-2 to tight junctions and its separation from 14-3-3. Molecular biology of the cell 16 31318316
2013 Beyond cell-cell adhesion: Emerging roles of the tight junction scaffold ZO-2. Tissue barriers 14 24665396
2009 The tight junction protein ZO-2 mediates proliferation of vascular smooth muscle cells via regulation of Stat1. Cardiovascular research 14 19380416
2023 Treatment with an ileal bile acid transporter inhibitor in patients with TJP2 deficiency. Clinics and research in hepatology and gastroenterology 13 37499899
2017 PARP‑1 may be involved in hydroquinone‑induced apoptosis by poly ADP‑ribosylation of ZO‑2. Molecular medicine reports 13 28983606
1998 Protein-binding domains of the tight junction protein, ZO-2, are highly conserved between avian and mammalian species. Biochemical and biophysical research communications 13 9837755
2023 ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation. Cell death & disease 12 36966163
2013 Alu-related transcript of TJP2 gene as a marker for colorectal cancer. Gene 12 23612256
2002 [LIM protein KyoT2 interacts with human tight junction protein ZO-2-i3]. Yi chuan xue bao = Acta genetica Sinica 12 12645256
2023 GNAQ-Regulated ZO-1 and ZO-2 Act as Tumor Suppressors by Modulating EMT Potential and Tumor-Repressive Microenvironment in Lung Cancer. International journal of molecular sciences 11 37240145
2021 ZO-2 favors Hippo signaling, and its re-expression in the steatotic liver by AMPK restores junctional sealing. Tissue barriers 11 34689705
2022 ZO-2/Tjp2 suppresses Yap and Wwtr1/Taz-mediated hepatocyte to cholangiocyte transdifferentiation in the mouse liver. NPJ Regenerative medicine 10 36151109
2021 Tight junction protein ZO-2 modulates the nuclear accumulation of transcription factor TEAD. Molecular biology of the cell 10 34010016
2011 The tight junction protein ZO-2 and Janus kinase 1 mediate intercellular communications in vascular smooth muscle cells. Biochemical and biophysical research communications 10 21679692
2021 Two Novel Pathogenic Variants of TJP2 Gene and the Underlying Molecular Mechanisms in Progressive Familial Intrahepatic Cholestasis Type 4 Patients. Frontiers in cell and developmental biology 9 34504838
2015 Chronic hypoxia down-regulates tight junction protein ZO-2 expression in children with cyanotic congenital heart defect. ESC heart failure 9 27398226
2003 Dynamic assembly of tight junction-associated proteins ZO-1, ZO-2, ZO-3 and occludin during mouse tooth development. Histology and histopathology 9 12507281
2024 The Role of ZO-2 in Modulating JAM-A and γ-Actin Junctional Recruitment, Apical Membrane and Tight Junction Tension, and Cell Response to Substrate Stiffness and Topography. International journal of molecular sciences 8 38473701
2019 ZO-2 Suppresses Cell Migration Mediated by a Reduction in Matrix Metalloproteinase 2 in Claudin-18-Expressing Lung Adenocarcinoma A549 Cells. Biological & pharmaceutical bulletin 8 30713254
2024 Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis. Hepatology (Baltimore, Md.) 6 38447037
2024 A ZO-2 scaffolding mechanism regulates the Hippo signalling pathway. The FEBS journal 4 39462647
2023 Silenced LASP1 interacts with DNMT1 to promote TJP2 expression and attenuate articular cartilage injury in mice by suppressing TJP2 methylation. The Kaohsiung journal of medical sciences 4 37578083
2023 p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP. Cell reports 4 37995182
2022 Polyubiquitination and SUMOylation Sites Regulate the Stability of ZO-2 Protein and the Sealing of Tight Junctions. Cells 4 36291162
2023 Transcriptomic Analysis of Tight Junction Proteins Demonstrates the Aberrant Expression and Function of Zona Occludens 2 (ZO-2) Protein in Stanford Type A Aortic Dissection. Journal of personalized medicine 3 38138924
2025 Rotenone inhibited osteosarcoma metastasis by modulating ZO-2 expression and location via the ROS/Ca2+/AMPK pathway. Redox report : communications in free radical research 2 40247635
2023 p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor suppressor function mediated by p190A RhoGAP. bioRxiv : the preprint server for biology 2 37292741
2016 [Progressive familial intrahepatic cholestasis related to mutation of the TJP2 gene: recent advances]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2 26983395
2024 Molecular alterations associated with pathophysiology in liver-specific ZO-1 and ZO-2 knockout mice. Cell structure and function 1 39322562
2021 Case Report: A Novel Single Variant TJP2 Mutation in a Case of Benign Recurrent Intrahepatic Cholestasis. JPGN reports 1 37205944
2026 ZO-2 determines cell membrane localization of receptor NTCP and supports hepatitis B virus infection. mBio 0 41870046
2026 RBM15 drives bladder cancer progression through YTHDF2-dependent m6A-mediated regulation of ZO2. Journal of experimental & clinical cancer research : CR 0 41913267
2026 Simultaneous TFAM and TJP2 Variants in a Child With Cirrhosis and Hepatocellular Carcinoma. Pediatrics 0 42082186
2025 Contact and communication: ZO-2 and the Hippo pathway. The FEBS journal 0 39910408
2025 Report of a missense TJP2 variant associated to PFIC4 with a pronounced phenotypic variability: Focus on the structural effects on the protein level. Journal of human genetics 0 40251428
2025 ZO-2 is a scaffold at the centriole and mitotic spindle poles that enhances microtubule stability and supports the proper development of mitotic spindles and cilia. Cell and tissue research 0 40728639
2025 ZO-1/Tjp1 and ZO-2/Tjp2 deletion in retinal pigment epithelium causes progressive retinal degeneration. iScience 0 41210963
2025 c-Abl Kinase Targets Tight Junction Protein ZO-2 in Regulation of Cell Migration and Morphology. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 0 41259016

Missed literature

Know a paper Affinage missed for TJP2? Flag it for the maintainers and the community.

No submissions yet.